Overview

Phase 3 Study of Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

Status:
Not yet recruiting

Trial end date:
2025-03-04

Target enrollment:

Participant gender:

Summary

UP-NEXT is a double-blind, randomized, placebo controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion for patients once every four weeks. Patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC) including fallopian tube and primary peritoneal cancer expressing high levels of NaPi2b.

Phase:

Phase 3

Details

Lead Sponsor:

Mersana Therapeutics

Collaborators:

European Network of Gynaecological Oncological Trial Groups (ENGOT)
GOG Foundation

Treatments:

Immunoconjugates